Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Continuing the steady stream of favorable and swift FDA approvals regarding Diabetes technology, yet another landmark decision came in Dexcom’s favor over the weekend. The FDA approved a new version of the Dexcom Share platform, which will make the Dexcom G4 continuous glucose monitor (CGM) the first on the market to be able to wirelessly transmit glucose readings directly to an iPhone.
The original Dexcom Share, ($299, pictured below), which itself had just received FDA approval October 2014, was a docking cradle peripheral that could transmit Dexcom’s glucose readings to a nearby iPhone, which then uploaded glucose readings through the cloud to concerned family members or caregivers. However, the original Share solution required an entirely separate dock, which made it only viable for sedentary settings like overnight monitoring or monitoring while in a room at daycare.
http://www.imedicalapps.com/2015/01/fda-approves-diabetes-app/
The original Dexcom Share, ($299, pictured below), which itself had just received FDA approval October 2014, was a docking cradle peripheral that could transmit Dexcom’s glucose readings to a nearby iPhone, which then uploaded glucose readings through the cloud to concerned family members or caregivers. However, the original Share solution required an entirely separate dock, which made it only viable for sedentary settings like overnight monitoring or monitoring while in a room at daycare.
http://www.imedicalapps.com/2015/01/fda-approves-diabetes-app/